Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 19, 2012 02:00 ET | Source: Idenix Pharmaceuticals

Idenix Pharmaceuticals Provides Update on Hepatitis C Clinical Development Programs

IDX719 Demonstrates Pan-Genotypic Activity at Single Doses in HCV-Infected Patients Achieving Greater Than 3 log10 Viral Load Reductions in the 100 mg Dose Group Across Genotypes 1, 2 and 3;...